Michael Edward Johnston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Edward Johnston has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Sameer H. Patel
Department of Surgery, Division of Surgical Oncology, University of Cincinnati College of Medicine, Cincinnati, USA
2 shared publications - Aaron M. Delman
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
1 shared publication - Al-Faraaz Kassam
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
1 shared publication Alexander Bondoc
Division of General and Thoracic Surgery,Cincinnati Children’s Hospital Medical Center,Cincinnati,OH
1 shared publicationAlexander R. Cortez
Cincinnati Children's Hospital Medical Center, Division of Pediatric General and Thoracic Surgery, Cincinnati, OH, USA; University of Cincinnati Medical Center, Department of Surgery, Cincinnati, OH, USA
1 shared publicationAurore Gorse
XenTech 4,Évry‐Courcouronnes,France
1 shared publication
Latest Publications
- Open Access
Fluorescent‐guided surgery and the use of indocyanine green sentinel lymph node mapping in the pediatric and young adult oncology population
Background: Technetium‐99 (99mTc) lymphoscintigraphy with blue dye injection is an accepted method for sentinel lymph node (SLN) mapping, but blue dye has known adverse effects, and injection of 99mTc may increase time under anesthesia for pediatric patients. Indocyanine green (ICG) may serve as an adjunct to assist with visibility and identification of SLNs. We hypothesized that sensitivity of ICG was similar to blue dye in SLN biopsies.Methods: Thirty patients (36 procedures with 96 total specimens) underwent preoperative intradermal injection of 99mTc, followed by intradermal injection of isosulfan blue and ICG. Test characteristics of blue dye, ICG, and 99mTc included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).Results: ICG had a sensitivity of 87% and PPV of 83% for detection of 99mTc‐hot lymph nodes; blue dye had a sensitivity of 44% and PPV of 97%. For detection of pathologically confirmed lymph nodes, ICG had a sensitivity of 84% and a positive predictive value (PPV) of 91%. 99mTc had a sensitivity of 82% and a PPV of 94%. ICG had no significant difference in odds of being positive in pathology‐confirmed lymph nodes compared to 99mTc (odds ratio [OR], 0.818; 95% confidence interval [CI], 0.3–2.172; p = .823) and had higher odds than isosulfan blue (OR, 0.025, 95% CI, 0.001–0.148; p < .001).Conclusion: This study established the efficacy of ICG as an adjunct to SLNB in the pediatric and young adult population. ICG was safe, more efficacious than blue dye, and may obviate the need for lymphoscintigraphy in selected patients resulting in reduced time under anesthesia.
Open AccessFluorescent‐guided surgery and the use of indocyanine green sentinel lymph node mapping in the pediatric and young adult oncology population
Background: Technetium‐99 (99mTc) lymphoscintigraphy with blue dye injection is an accepted method for sentinel lymph node (SLN) mapping, but blue dye has known adverse effects, and injection of 99mTc may increase time under anesthesia for pediatric patients. Indocyanine green (ICG) may serve as an adjunct to assist with visibility and identification of SLNs. We hypothesized that sensitivity of ICG was similar to blue dye in SLN biopsies.Methods: Thirty patients (36 procedures with 96 total specimens) underwent preoperative intradermal injection of 99mTc, followed by intradermal injection of isosulfan blue and ICG. Test characteristics of blue dye, ICG, and 99mTc included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).Results: ICG had a sensitivity of 87% and PPV of 83% for detection of 99mTc‐hot lymph nodes; blue dye had a sensitivity of 44% and PPV of 97%. For detection of pathologically confirmed lymph nodes, ICG had a sensitivity of 84% and a positive predictive value (PPV) of 91%. 99mTc had a sensitivity of 82% and a PPV of 94%. ICG had no significant difference in odds of being positive in pathology‐confirmed lymph nodes compared to 99mTc (odds ratio [OR], 0.818; 95% confidence interval [CI], 0.3–2.172; p = .823) and had higher odds than isosulfan blue (OR, 0.025, 95% CI, 0.001–0.148; p < .001).Conclusion: This study established the efficacy of ICG as an adjunct to SLNB in the pediatric and young adult population. ICG was safe, more efficacious than blue dye, and may obviate the need for lymphoscintigraphy in selected patients resulting in reduced time under anesthesia.
- 1 October 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 222 (4) , 786-792
Total pancreatectomy with islet autotransplantation reduces resource utilization in pediatric patients
- 1 October 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 222 (4) , 786-792
Total pancreatectomy with islet autotransplantation reduces resource utilization in pediatric patients
- Open Access
- 26 May 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (4) , 2201-2215
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft Models
Background and Aims: Hepatoblastoma (HBL) is a devastating pediatric liver cancer with multiple treatment options, but it ultimately requires surgery for a cure. The most malicious form of HBL is a chemo‐resistant aggressive tumor that is characterized by rapid growth, metastases, and poor response to treatment. Very little is known of the mechanisms of aggressive HBL, and recent focuses have been on developing alternative treatment strategies. In this study, we examined the role of human chromosomal regions, called aggressive liver cancer domains (ALCDs), in liver cancer and evaluated the mechanisms that activate ALCDs in aggressive HBL. Results: We found that ALCDs are critical regions of the human genome that are located on all human chromosomes, preferentially in intronic regions of the oncogenes and other cancer‐associated genes. In aggressive HBL and in patients with Hepatocellular (HCC), JNK1/2 phosphorylates p53 at Ser6, which leads to the ph‐S6‐p53 interacting with and delivering the poly(adenosine diphosphate ribose) polymerase 1 (PARP1)/Ku70 complexes on the oncogenes containing ALCDs. The ph‐S6‐p53‐PARP1 complexes open chromatin around ALCDs and activate multiple oncogenic pathways. We found that the inhibition of PARP1 in patient‐derived xenografts (PDXs) from aggressive HBL by the Food and Drug Administration (FDA)–approved inhibitor olaparib (Ola) significantly inhibits tumor growth. Additionally, this is associated with the reduction of the ph‐S6‐p53/PARP1 complexes and subsequent inhibition of ALCD‐dependent oncogenes. Studies in cultured cancer cells confirmed that the Ola‐mediated inhibition of the ph‐S6‐p53‐PARP1‐ALCD axis inhibits proliferation of cancer cells. Conclusions: In this study, we showed that aggressive HBL is moderated by ALCDs, which are activated by the ph‐S6‐p53/PARP1 pathway. By using the PARP1 inhibitor Ola, we suppressed tumor growth in HBL‐PDX models, which demonstrated its utility in future clinical models.
- 26 May 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (4) , 2201-2215
Open AccessOlaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft Models
Background and Aims: Hepatoblastoma (HBL) is a devastating pediatric liver cancer with multiple treatment options, but it ultimately requires surgery for a cure. The most malicious form of HBL is a chemo‐resistant aggressive tumor that is characterized by rapid growth, metastases, and poor response to treatment. Very little is known of the mechanisms of aggressive HBL, and recent focuses have been on developing alternative treatment strategies. In this study, we examined the role of human chromosomal regions, called aggressive liver cancer domains (ALCDs), in liver cancer and evaluated the mechanisms that activate ALCDs in aggressive HBL. Results: We found that ALCDs are critical regions of the human genome that are located on all human chromosomes, preferentially in intronic regions of the oncogenes and other cancer‐associated genes. In aggressive HBL and in patients with Hepatocellular (HCC), JNK1/2 phosphorylates p53 at Ser6, which leads to the ph‐S6‐p53 interacting with and delivering the poly(adenosine diphosphate ribose) polymerase 1 (PARP1)/Ku70 complexes on the oncogenes containing ALCDs. The ph‐S6‐p53‐PARP1 complexes open chromatin around ALCDs and activate multiple oncogenic pathways. We found that the inhibition of PARP1 in patient‐derived xenografts (PDXs) from aggressive HBL by the Food and Drug Administration (FDA)–approved inhibitor olaparib (Ola) significantly inhibits tumor growth. Additionally, this is associated with the reduction of the ph‐S6‐p53/PARP1 complexes and subsequent inhibition of ALCD‐dependent oncogenes. Studies in cultured cancer cells confirmed that the Ola‐mediated inhibition of the ph‐S6‐p53‐PARP1‐ALCD axis inhibits proliferation of cancer cells. Conclusions: In this study, we showed that aggressive HBL is moderated by ALCDs, which are activated by the ph‐S6‐p53/PARP1 pathway. By using the PARP1 inhibitor Ola, we suppressed tumor growth in HBL‐PDX models, which demonstrated its utility in future clinical models.
- 1 February 2019
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 35 (1) , 53-63
Surgical Oncology and Geriatric Patients
- 1 February 2019
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 35 (1) , 53-63
Surgical Oncology and Geriatric Patients
- 1 June 2017
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 27 (3) , e40-e43
Laparoscopic Gastroepiploic Lymphovascular Pedicle Harvesting for the Treatment of Extremity Lymphedema: A Novel Technique
Vascularized lymph node transfers have multiple donor sites with risk of iatrogenic lymphedema. We sought to describe in detail a surgical technique that is safe, reproducible, and efficient in harvesting gastroepiploic vascularized lymph nodes using real-time indocyanine green (ICG) fluorescent imaging. Photographs and video were acquired from a case to depict a step-by-step approach. ICG was endoscopically injected into the submucosa of the greater curvature of the stomach at the outset of the procedure. A laparoscopic harvest of the gastroepiploic vascular pedicle and lymph nodes ensued with the assistance of fluorescent imaging. Laparoscopic gastroepiploic lymph node harvesting aided by real-time ICG fluorescent mapping technique is safe, feasible, and effective at gathering vascularized lymphatic tissue for successful lymph node transfer in patients with severe lymphedema.
- 1 June 2017
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 27 (3) , e40-e43
Laparoscopic Gastroepiploic Lymphovascular Pedicle Harvesting for the Treatment of Extremity Lymphedema: A Novel Technique
Vascularized lymph node transfers have multiple donor sites with risk of iatrogenic lymphedema. We sought to describe in detail a surgical technique that is safe, reproducible, and efficient in harvesting gastroepiploic vascularized lymph nodes using real-time indocyanine green (ICG) fluorescent imaging. Photographs and video were acquired from a case to depict a step-by-step approach. ICG was endoscopically injected into the submucosa of the greater curvature of the stomach at the outset of the procedure. A laparoscopic harvest of the gastroepiploic vascular pedicle and lymph nodes ensued with the assistance of fluorescent imaging. Laparoscopic gastroepiploic lymph node harvesting aided by real-time ICG fluorescent mapping technique is safe, feasible, and effective at gathering vascularized lymphatic tissue for successful lymph node transfer in patients with severe lymphedema.
- Open Access
- 3 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 20788-20800
Radiation therapy generates platelet-activating factor agonists
Radiation therapy generates platelet-activating factor agonists
- 3 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 20788-20800
Open AccessRadiation therapy generates platelet-activating factor agonists
Radiation therapy generates platelet-activating factor agonists